A study of rheumatoid arthritis management with the triple combination of methotrexate + hydroxychloroquine + sulfasalazine and double combination of methotrexate + hydroxychloroquine
Rheumatoid arthritis is chronic multisystem disease, failure rate with monotherapy is high. The present study was designed to compare the efficacy and safety of triple combination of Methotrexate + Hydroxychloroquine + Sulfasalazine and double combination of Methotrexate + Hydroxychloroquine in patients suffering from Rheumatoid Arthritis. The present study was a prospective, randomized, single blind comparative study of 24 weeks duration. 60 patients were included which were assigned two groups, A and B with 30 patients in each group. Group A was given Methotrexate (MTX) 7.5 mg once a week + Hydroxychloroquine (HCQ) 200mg OD + Sulfasalazine (SSZ) 500 mg BD and Group B was given Methotrexate 7.5 mg once a week + Hydroxychloroquine 200 mg OD. The patients were evaluated for clinical efficacy and safety using different clinical and laboratory parameters. There was a significant reduction in various parameters in group A as compared to group B indicating superiority of the triple combination over the double combination. Based on our findings we suggest that the triple combination of MTX, HCQ and SSZ is more efficacious and equally tolerable than the double combination of MTX and SSZ in patients suffering from RA.
Full Text Attachment